Generic Name and Formulations:
Hydrocodone bitartrate, acetaminophen; 5mg/300mg, 7.5mg/300mg, 10mg/300mg; tabs.
Various generic manufacturers
Indications for Hydrocodone/Acetaminophen:
Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Use lowest effective dose for shortest duration. Individualize. Give every 4–6hrs as needed. Initially 1–2 tabs of 5mg/300mg (max 8 tabs/day) or 1 tab of 7.5mg/300mg or 10mg/300mg (max 6 tabs/day). Renal or hepatic impairment: initiate at lower doses; monitor. Concomitant use or discontinuation of CYP3A4 inhibitors or inducers: monitor closely and consider dose adjustments (see full labeling). Withdraw gradually by 25–50% every 2–4 days.
Significant respiratory depression. Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment. Known or suspected GI obstruction, including paralytic ileus.
Life-threatening respiratory depression; monitor within first 24–72hrs of initiating therapy and following dose increases. Accidental exposure may cause fatal overdose (esp. in children). COPD, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression; monitor and consider non-opioid analgesics. Abuse potential (monitor). Increased risk of hepatotoxicity with acetaminophen doses >4g/day, alcohol abusers. Underlying liver disease. Adrenal insufficiency. Head injury. Increased intracranial pressure, brain tumors; monitor. Seizure disorders. CNS depression. Impaired consciousness, coma, shock; avoid. Biliary tract disease. Acute pancreatitis. Discontinue at the 1st sign of rash or any other hypersensitivity. Drug abusers. Renal or hepatic impairment. Reevaluate periodically. Avoid abrupt cessation. Elderly. Cachectic. Debilitated. Labor & delivery: not recommended. Pregnancy (Cat.C); potential neonatal opioid withdrawal syndrome during prolonged use. Nursing mothers: monitor infants.
Increased risk of hypotension, respiratory depression, sedation with benzodiazepines or other CNS depressants (eg, non-benzodiazepine sedatives/hypnotics, anxiolytics, general anesthetics, phenothiazines, tranquilizers, muscle relaxants, antipsychotics, alcohol, other opioids); reserve concomitant use in those for whom alternative options are inadequate; limit dosages/durations to minimum required; monitor. During or within 14 days of MAOIs: not recommended. Avoid concomitant other acetaminophen-containing products. Risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, 5-HT3 antagonists, mirtazapine, trazodone, tramadol, MAOIs, linezolid, IV methylene blue); monitor and discontinue if suspected. Avoid concomitant mixed agonist/antagonist opioids (eg, butorphanol, nalbuphine, pentazocine) or partial agonist (eg, buprenorphine); may reduce effects and/or precipitate withdrawal symptoms. Potentiated by CYP3A4 inhibitors (eg, macrolides, azole antifungals, protease inhibitors). Antagonized by CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin). May antagonize diuretics; monitor. Paralytic ileus may occur with anticholinergics. May cause false (+) urine test for 5-hydroxyindoleacetic acid.
Opioid + analgesic.
Lightheadedness, dizziness, sedation, other CNS effects, nausea, vomiting; respiratory depression, severe hypotension, syncope, hepatotoxicity (overdosage); rare: serious skin or hypersensitivity reactions.
Formerly known under the brand names Vicodin, Vicodin ES, Vicodin HP.
Endocrinology Advisor Articles
- Predictors of Success for Insulin-to-Liraglutide Switch for Type 2 Diabetes
- Efficacy and Safety of Alirocumab in Diabetes Mellitus
- Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes
- Transgender Youth Not Willing to Delay Hormone Therapy for Fertility Preservation
- Pre-Pregnancy Programs May Improve Outcomes in Women With Type 2 Diabetes
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- IV Fluid Infusion Rates Do Not Affect Pediatric DKA Neurologic Outcomes
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Psychiatric Morbidity Decreased After Assisted Reproductive Technology Treatment
- Fenofibrate Improves Cholesterol Levels in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk